Publikace
- Intensive Care Infection Score (ICIS) is elevated in patients with moderate and severe COVID-19 in the early stages of disease2022 | Lékařská fakulta v Hradci Králové
- Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia2021 | Lékařská fakulta v Hradci Králové, 3. lékařská fakulta
- Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome2021 | Lékařská fakulta v Hradci Králové
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group2020 | Lékařská fakulta v Hradci Králové, 1. lékařská fakulta, 3. lékařská fakulta
- IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?2018 | Lékařská fakulta v Hradci Králové
- COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status2017 | Lékařská fakulta v Hradci Králové
- Risk and Prognostic Factors in Cerebral Venous Thrombosis2017 | Lékařská fakulta v Hradci Králové
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Lékařská fakulta v Hradci Králové
- Venous thromboembolism in patients with chronic lymphocytic leukemia2015 | Lékařská fakulta v Hradci Králové
- Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia2014 | Lékařská fakulta v Hradci Králové
Loading network view...